{
    "2018-06-15": [
        [
            {
                "time": "",
                "original_text": "贝达药业：正推进MRX-2843申报国内临床试验的准备工作",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "MRX-2843",
                        "临床试验",
                        "准备工作"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：埃克替尼医保放量 立足中国创新全球",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "埃克替尼",
                        "医保放量",
                        "中国创新",
                        "全球市场"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}